{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:25:21Z","timestamp":1790760321082,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.lungcan.2021.11.011","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T15:57:47Z","timestamp":1638374267000},"page":"19-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer"],"prefix":"10.1016","volume":"163","author":[{"given":"Ruth","family":"Plummer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik-Tobias","family":"Arkenau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Redfern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander I.","family":"Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Melear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Y.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Ferrer-Playan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Goddemeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Fleuranceau-Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Diaz-Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey I.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2021.11.011_b0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","article-title":"Molecular mechanisms of resistance and toxicity associated with platinating agents","volume":"33","author":"Rabik","year":"2007","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.lungcan.2021.11.011_b0010","unstructured":"N.A. Howlader, M. Krapcho, J. Garshell, N. Neyman, S.F. Altekruse, C.L. Kosary, M. Yu, J. Ruhl, Z. Tatalovich, H. Cho, A. Mariotto, D.R. Lewis, H.S. Chen, E.J. Feuer, K.A. Cronin, SEER Cancer Statistics Review, 1975-2010, 2013. http:\/\/seer.cancer.gov\/csr\/1975_2010\/sections.html."},{"issue":"8","key":"10.1016\/j.lungcan.2021.11.011_b0015","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/annonc\/mdu123","article-title":"2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line\/second and further lines of treatment in advanced disease","volume":"25","author":"Besse","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.lungcan.2021.11.011_b0020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11864-006-0030-9","article-title":"Second- and third-line treatments in non-small cell lung cancer","volume":"7","author":"Kumar","year":"2006","journal-title":"Curr. Treat. Options Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2021.11.011_b0025","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3816\/CLC.2007.n.001","article-title":"Open, randomized, phase II study of single-agent gemcitabine and docetaxel as first- and second-line treatment in patients with advanced non-small-cell lung cancer","volume":"8","author":"Manegold","year":"2007","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.lungcan.2021.11.011_b0030","doi-asserted-by":"crossref","unstructured":"Y.H. Ko, M.A. Lee, Y.S. Hong, K.S. Lee, H.J. Park, R. Yoo Ie, Y.S. Kim, Y.K. Kim, K.H. Jo, Y.P. Wang, K.Y. Lee, J.H. Kang, Docetaxel monotherapy as second-line treatment for pretreated advanced non-small cell lung cancer patients, Korean J. Intern. Med. 22(3) (2007) 178-85 10.3904\/kjim.2007.22.3.178.","DOI":"10.3904\/kjim.2007.22.3.178"},{"issue":"6","key":"10.1016\/j.lungcan.2021.11.011_b0035","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1159\/000502343","article-title":"Efficacy of vinorelbine monotherapy as third- or further-line therapy in patients with advanced non-small-cell lung cancer","volume":"97","author":"Kang","year":"2019","journal-title":"Oncology"},{"key":"10.1016\/j.lungcan.2021.11.011_b0040","doi-asserted-by":"crossref","unstructured":"A.N. Blackford, S.P. Jackson, ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response, Mol. Cell 66(6) (2017) 801-817 10.1016\/j.molcel.2017.05.015.","DOI":"10.1016\/j.molcel.2017.05.015"},{"issue":"1","key":"10.1016\/j.lungcan.2021.11.011_b0045","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2897","article-title":"Causes and consequences of replication stress","volume":"16","author":"Zeman","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.lungcan.2021.11.011_b0050","doi-asserted-by":"crossref","unstructured":"A.B. Hall, D. Newsome, Y. Wang, D.M. Boucher, B. Eustace, Y. Gu, B. Hare, M.A. Johnson, S. Milton, C.E. Murphy, D. Takemoto, C. Tolman, M. Wood, P. Charlton, J.D. Charrier, B. Furey, J. Golec, P.M. Reaper, J.R. Pollard, Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970, Oncotarget. 5(14) (2014) 5674-85 10.18632\/oncotarget.2158.","DOI":"10.18632\/oncotarget.2158"},{"key":"10.1016\/j.lungcan.2021.11.011_b0055","doi-asserted-by":"crossref","unstructured":"T.A. Yap, B. O'Carrigan, M.S. Penney, J.S. Lim, J.S. Brown, M.J. de Miguel Luken, N. Tunariu, R. Perez-Lopez, D.N. Rodrigues, R. Riisnaes, I. Figueiredo, S. Carreira, B. Hare, K. McDermott, S. Khalique, C.T. Williamson, R. Natrajan, S.J. Pettitt, C.J. Lord, U. Banerji, J. Pollard, J. Lopez, J.S. de Bono, Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors, J. Clin. Oncol. 38(27) (2020) 3195-3204 10.1200\/JCO.19.02404.","DOI":"10.1200\/JCO.19.02404"},{"key":"10.1016\/j.lungcan.2021.11.011_b0060","doi-asserted-by":"crossref","unstructured":"P.A. Konstantinopoulos, S.C. Cheng, A.E. Wahner Hendrickson, R.T. Penson, S.T. Schumer, L.A. Doyle, E.K. Lee, E.C. Kohn, L.R. Duska, M.A. Crispens, A.B. Olawaiye, I.S. Winer, L.M. Barroilhet, S. Fu, M.T. McHale, R.J. Schilder, A. Farkkila, D. Chowdhury, J. Curtis, R.S. Quinn, B. Bowes, A.D. D'Andrea, G.I. Shapiro, U.A. Matulonis, Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial, Lancet Oncol. 21(7) (2020) 957-968 10.1016\/S1470-2045(20)30180-7.","DOI":"10.1016\/S1470-2045(20)30180-7"},{"key":"10.1016\/j.lungcan.2021.11.011_b0065","doi-asserted-by":"crossref","unstructured":"A. Thomas, N. Takahashi, V.N. Rajapakse, X. Zhang, Y. Sun, M. Ceribelli, K.M. Wilson, Y. Zhang, E. Beck, L. Sciuto, S. Nichols, B. Elenbaas, J. Puc, H. Dahmen, A. Zimmermann, J. Varonin, C.W. Schultz, S. Kim, H. Shimellis, P. Desai, C. Klumpp-Thomas, L. Chen, J. Travers, C. McKnight, S. Michael, Z. Itkin, S. Lee, A. Yuno, M.-J. Lee, C.E. Redon, J.D. Kindrick, C.J. Peer, J.S. Wei, M.I. Aladjem, W.D. Figg, S.M. Steinberg, J.B. Trepel, F.T. Zenke, Y. Pommier, J. Khan, C.J. Thomas, Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress, Cancer Cell. 39(4) (2021) 566-579.e7 10.1016\/j.ccell.2021.02.014.","DOI":"10.1016\/j.ccell.2021.02.014"},{"issue":"7","key":"10.1016\/j.lungcan.2021.11.011_b0070","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat. Chem. Biol."},{"issue":"5","key":"10.1016\/j.lungcan.2021.11.011_b0075","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrc3711","article-title":"Unravelling mechanisms of p53-mediated tumour suppression","volume":"14","author":"Bieging","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lungcan.2021.11.011_b0080","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/583929","article-title":"TP53 mutations in nonsmall cell lung cancer","volume":"2011","author":"Mogi","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.lungcan.2021.11.011_b0085","article-title":"First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors","author":"Yap","year":"2020","journal-title":"Cancer Discov"},{"issue":"18","key":"10.1016\/j.lungcan.2021.11.011_b0090","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1158\/0008-5472.CAN-20-1744","article-title":"BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency","volume":"80","author":"Gupta","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2021.11.011_b0095","doi-asserted-by":"crossref","first-page":"13837","DOI":"10.1038\/ncomms13837","article-title":"ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A","volume":"7","author":"Williamson","year":"2016","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.lungcan.2021.11.011_b0100","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1158\/2159-8290.CD-19-0338","article-title":"Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11","volume":"9","author":"Lang","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2021.11.011_b0105","doi-asserted-by":"crossref","unstructured":"H. Ogiwara, K. Takahashi, M. Sasaki, T. Kuroda, H. Yoshida, R. Watanabe, A. Maruyama, H. Makinoshima, F. Chiwaki, H. Sasaki, T. Kato, A. Okamoto, T. Kohno, Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers, Cancer Cell. 35(2) (2019) 177-190.e8 10.1016\/j.ccell.2018.12.009.","DOI":"10.1016\/j.ccell.2018.12.009"},{"key":"10.1016\/j.lungcan.2021.11.011_b0110","doi-asserted-by":"crossref","unstructured":"M.R. Middleton, E. Dean, T.R.J. Evans, G.I. Shapiro, J. Pollard, B.S. Hendriks, M. Falk, I. Diaz-Padilla, R. Plummer, Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine \u00b1 cisplatin in patients with advanced solid tumours, British Journal of Cancer (2021) 10.1038\/s41416-021-01405-x.","DOI":"10.1038\/s41416-021-01405-x"},{"issue":"4","key":"10.1016\/j.lungcan.2021.11.011_b0115","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/s41416-021-01406-w","article-title":"Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours","volume":"125","author":"Shapiro","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2021.11.011_b0120","doi-asserted-by":"crossref","unstructured":"E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer 45(2) (2009) 228-47 10.1016\/j.ejca.2008.10.026.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"10.1016\/j.lungcan.2021.11.011_b0125","doi-asserted-by":"crossref","unstructured":"J. Pollard P. Reaper A. Peek S. Hughes S. Gladwell J. Jones P. Chiu M. Wood C. Tolman M. Johnson P. Littlewood M. Penney K. McDermott B. Hare S.Z. Fields M. Asmal B. O\u2019Carrigan T.A. Yap Abstract 3717: Defining optimal dose schedules for ATR inhibitors in combination with DNA damaging drugs: Informing clinical studies of VX-970, the first-in-class ATR inhibitor Cancer Res 76 14 Supplement 2016 3717 3717 10.1158\/1538-7445.Am2016-3717.","DOI":"10.1158\/1538-7445.AM2016-3717"},{"key":"10.1016\/j.lungcan.2021.11.011_b0130","unstructured":"MedDRA, Medical Dictionary for Regulatory Activities Version 21.0, 2018. https:\/\/admin.new.meddra.org\/sites\/default\/files\/guidance\/file\/dist_file_format_21_0_english.pdf."},{"key":"10.1016\/j.lungcan.2021.11.011_b0135","unstructured":"NCI, Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0, 2009. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf."},{"issue":"4","key":"10.1016\/j.lungcan.2021.11.011_b0140","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The Use of Confidence or Fiducial Limits Illustrated in the Case of the Binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1016\/j.lungcan.2021.11.011_b0145","unstructured":"C. Medpace Bioanalytical Laboratories, OH, USA., Validation of an LC\/MS\/MS Bioanalytical Method for the Determination of VX-970 Concentration in Human K2EDTA Plasma, MBL Study No. MBL13206, Report No. RPT13206 and Report Amendment No\u2019s RPT13206-1, 1A and RPT13206-2, 2A."},{"key":"10.1016\/j.lungcan.2021.11.011_b0150","unstructured":"Foundation Medicine, FoundationOne\u00aeCDx Technical Information. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf17\/P170019S006C.pdf. (Accessed 27 January 2021)."},{"key":"10.1016\/j.lungcan.2021.11.011_b0155","unstructured":"FDA, FoundationFocus CDxBRCA LOH - P160018\/S001, 2018. https:\/\/www.fda.gov\/medical-devices\/recently-approved-devices\/foundationfocus-cdxbrca-loh-p160018s001. (Accessed 27 January 2021)."},{"issue":"2","key":"10.1016\/j.lungcan.2021.11.011_b0160","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00280-020-04184-z","article-title":"Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types","volume":"87","author":"Terranova","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.lungcan.2021.11.011_b0165","doi-asserted-by":"crossref","unstructured":"L.M.F. Primo, L.K. Teixeira, DNA replication stress: oncogenes in the spotlight, Genet Mol Biol 43(1 suppl 1) (2019) e20190138 10.1590\/1678-4685GMB-2019-0138.","DOI":"10.1590\/1678-4685gmb-2019-0138"},{"issue":"10","key":"10.1016\/j.lungcan.2021.11.011_b0170","doi-asserted-by":"crossref","first-page":"R435","DOI":"10.1016\/j.cub.2014.04.012","article-title":"DNA replication and oncogene-induced replicative stress","volume":"24","author":"Hills","year":"2014","journal-title":"Curr. Biol."},{"issue":"10","key":"10.1016\/j.lungcan.2021.11.011_b0175","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/bjc.2012.451","article-title":"Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer","volume":"107","author":"Abkevich","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2021.11.011_b0180","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2017.76.8770","article-title":"Tumor mutation burden: leading immunotherapy to the era of precision medicine?","volume":"36","author":"Steuer","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2021.11.011_b0185","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s43018-021-00208-6","article-title":"ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer","volume":"2","author":"Deng","year":"2021","journal-title":"Nature Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2021.11.011_b0190","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111798","article-title":"Tumor mutational burden and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"11","author":"Kim","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"16 Supplement","key":"10.1016\/j.lungcan.2021.11.011_b0195","article-title":"Abstract 3548: Loss of heterozygosity (LOH) as a candidate biomarker of PARP inhibitor sensitivity in Chinese solid tumor patients","volume":"80","author":"Hu","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2021.11.011_b0200","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3389\/fonc.2020.00570","article-title":"Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors","volume":"10","author":"Vikas","year":"2020","journal-title":"Front. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221006048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221006048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T23:45:11Z","timestamp":1717544711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500221006048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":40,"alternative-id":["S0169500221006048"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.11.011","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}